Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease
Abstract Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without a reducti...
Main Authors: | Espen Thiis-Evensen, Amalie Christine Poole, Hong-Thien Thi Nguyen, Jon Sponheim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-06963-6 |
Similar Items
-
Radionuclide imaging and therapy in patients with neuroendocrine tumors
by: Olga D. Baranova, et al.
Published: (2018-03-01) -
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
by: Elena María Vida Navas, et al.
Published: (2021-04-01) -
Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
by: Hasegawa, S., et al.
Published: (2022) -
Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons
by: Ralph A. Bundschuh, et al.
Published: (2019-09-01) -
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01)